Citations

Clear

3042 citation(s) found for "Kumar, S".

Ventral intraspinal fluid-filled collection secondary to CSF leak presenting as bibrachial amyotrophy
DeLuca, Gabriele C. , Krueger, Bruce R, Mokri, Bahram, Kumar, Neeraj , Boes, Christopher J. , De Luca, Gabriele C

Mayo Clinic

Neurology | April 18, 2011 | Volume: 76 | Issue: 16 | Pages: 1439-1440

10.1212/wnl.0b013e3182166e6f | PMID 21502607 Get It

Abstract LB-128: Synthetic lethal RNAi screening identifies inhibition of Bcl-2 family members as sensitizers to 5-Azacytidine in myeloid cells
Bogenberger, James M. , Hagelstrom, Tanner, Gonzales, Irma M. , Tiedemann, Roger, Azorsa, David O. , Stewart, Keith, Tiedemann, Rodger E. , Shi, Chang-Xin , Choudhary, Ashish Kumar , Tibes, Raoul , Bogenberger, James

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: LB-128-LB-128

10.1158/1538-7445.am10-lb-128 Get It

Abstract In order to identify novel targets and clinically exploitable vulnerabilities, we performed high-throughput RNA-interference (RNAi) synthetic lethality screening using myeloid cell lines TF-1 and ML-2 in combination with the hypomethylating agent 5-Azacytidine. A custom small interfering RNA (siRNA) library targeting nearly 1000 cancer-associated genes, including the human kinome, was utilized. Bcl-XL emerged as the strongest 5-Azacytidine sensitizing target in the erythroid cell line TF-1 but not in ML-2 cells. Additional siRNA sequences targeting Bcl-XL were transfected into a panel of myeloid cell lines and tested in drug dose response experiments using a ten-point serial dilution of 5-Azacytidine. The erythroid differentiated myeloid cell lines TF-1 and HEL both exhibited a 3 to 4-fold reduction in the IC50 of 5-Azacytidine upon knockdown of Bcl-XL, whereas IC50 values for non-erythroid, myeloid cell lines ML-2, THP-1 and MDS-L were unchanged. Furthermore, we tested lentiviral delivery of short-hairpin RNA (shRNA) targeting Bcl-XL in additional cell lines. Lentiviral knockdown of Bcl-XL confirmed 2 to 3-fold 5-Azacytidine sensitization in TF-1 and HEL cells while U937, HL-60, ML-2, THP-1 and MDS-L were not sensitized by Bcl-XL knockdown. Interestingly, while Bcl-XL knockdown with shRNA potentiated the effects of 5-Azacytidine in TF-1 and HEL, Bcl-XL knockdown alone resulted in considerable reductions in cell viability in TF-1 and HEL cells. These results demonstrate erythroid lineage-specific responses to Bcl-XL knockdown and suggest that Bcl-XL may represent an erythroid lineage-specific therapeutic vulnerability. To begin to explore this possibility we examined the putative BH3 mimetics Gossypol, Obatoclax and ABT-737 with 5-Azacytidine drug dose response experiments in myeloid cell lines. Neither Gossypol nor Obatoclax potentiated the effects of 5-Azacytdine. In striking contrast, ABT-737 resulted in a 2 to 4-fold reduction in the IC50 of 5-Azacytidine in all cell lines tested to date (TF-1, HEL, ML-2 and THP-1). ABT-737 sensitization to 5-Azacytidine was dose dependent. Furthermore, Combination Index (CI) values calculated with Calcusyn software demonstrate synergy between ABT-737 and 5-Azacytidine at clinically relevant concentrations. These results suggest that inhibition of anti-apoptotic Bcl-2 family members with a BH3 mimetic may represent an effective strategy for 5-Azacytidine combination therapy that can be directly translated into design of combination clinical trials in patients with myeloid leukemias. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-128.
Abstract 1796: Significant in-vitro anti-myeloma activity of a novel Akt inhibitor MK2206
Haug, Jessica, Kimlinger, Teresa K. , Halling, Timothy, Wellik, Linda, Kumar, Shaji , Ramakrishnan, Vijay , Rajkumar, S. Vincent

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 1796-1796

10.1158/1538-7445.am10-1796 Get It

Abstract Background: Cytokine stimulated signaling pathways contribute to multiple myeloma (MM) disease progression and in acquired resistance to current treatment options making MM an incurable malignancy. The PI3K/Akt/mTOR pathway is up-regulated in MM and appears to be critical for cell proliferation and blocking this pathway might have profound impact on disease progression. In addition, this pathway also has been found to cross talk with other signal transduction pathways preventing drug-induced apoptosis. Methods: MK2206 was obtained from Merck Inc. MTT assay was performed to study drug induced cytotoxicity and thymidine uptake was used as a measure to study differences in proliferation. Flow cytometry using Annexin V-FITC and propidium iodide (PI) was used to measure drug induced apoptosis in cell lines and patient cells. In addition, apo-2.7 was also used to measure apoptosis in patient cells. Results: MK2206 treatment led to dose and time dependent decrease in cell viability as observed by MTT assay with an IC50 range of 1-5µM on most MM cell lines tested. Most of the cytotoxicity was observed by 48hours with minimal increase in cytotoxicity beyond that point. The drug was able to induce cytotoxicity in myeloma cell lines when cells were cultured with IGF, IL6, or VEGF with minimal increase in IC50 values. MK2206 also inhibited MM cell proliferation as observed by reduced thymidine uptake. This reduction in proliferation was also observed when MM cells were co-cultured with bone marrow stromal cells. When myeloma cell lines were treated with the drug for various time points, percentage of apoptotic cells increased with time of incubation with the drug as observed by flow cytometry and annexin V-FITC/PI staining. There was also a time dependent increase in caspase cleavage observed indicating that MK2206 might elicit its functions by inducing caspase dependent pathways. Further studies are being carried out to understand the importance of caspase dependent pathways for the success of anti-MM effects of MK2206. Also, MK2206 was able to induce apoptosis in patient derived primary cells, though with varying degrees of response observed between patients. Examining signaling pathways by immunoblotting demonstrated clear down regulation of pAkt and Bcl-xl levels post treatment with the drug with minimal decrease in proteins associated with other signaling pathways, like pSTAT3 and pERK. Conclusions: Taken together, our studies demonstrate significant anti-MM activity of MK2206 in-vitro. We are currently testing MK2206 in combination with known inhibitors of the other important signaling pathways implicated in MM disease biology as well as in-vivo experiments in mouse models. Performing these experiments will further validate the efficacy of MK2206 as an anti-MM agent and form the basis for it to be taken up for clinical evaluation either as a single agent or in combination with other agent(s). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1796.
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Dimopoulos, Meletios Α. , Kyle, Robert A. , Fermand, Jean-Paul, Rajkumar, S. Vincent , Miguel, Jesús F. San , Chanan‐Khan, Asher , Joshua, Douglas, Mehta, Jayesh, Avet‐Loiseau, Hervé , Beksaç, Meral , Moreau, Philippe , Goldschmidt, Hartmut , Boccadoro, Mario , Kumar, Shaji , Munshi, Nikhil C. , 3, on behalf of the International Myeloma Workshop Consensus Panel, Ludwig, Heinz , Gertz, Morie A. , Anderson, Kenneth C. , Singhal, Seema , Giralt, Sergio , Jagannath, Sundar , 3, on behalf of the International Myeloma Workshop Consensus Panel, Rajkumar, S Vincent , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Beksac, Meral

Mayo Clinic

Blood | February 4, 2011 | Volume: 117 | Issue: 18 | Pages: 4701-4705

10.1182/blood-2010-10-299529 | PMID 21292778 Get It

AbstractA panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitation is recommended, and immunofixation is required for confirmation. The serum-free light chain assay is recommended in all newly diagnosed patients with plasma cell dyscrasias. Bone marrow aspiration and/or biopsy along with demonstration of clonality of plasma cells are necessary. Serum β2-microglobulin, albumin, and lactate dehydrogenase are necessary for prognostic purposes. Standard metaphase cytogenetics and fluorescent in situ hybridization for 17p, t(4;14), and t(14;16) are recommended. The skeletal survey remains the standard method for imaging screening, but magnetic resonance imaging frequently provides valuable diagnostic and prognostic information. Most of these tests are repeated during follow-up or at relapse.
Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure
Maisel, William H., Friedman, Paul A. , Kallinen, Linda M., Mugglin, Andrew S. , Kumar, Kapil , Hodge, David O. , Morrison, Thomas B., Hayes, David L. , Hauser, Robert G.

Mayo Clinic

Circulation | January 18, 2011 | Volume: 123 | Issue: 4 | Pages: 358-363

10.1161/circulationaha.110.975219 | PMID 21242478 Get It

Background— Sprint Fidelis (Fidelis) implantable cardioverter-defibrillator leads are prone to fractures that have caused adverse events, primarily inappropriate shocks, and a few reported deaths. More than 100 000 patients have Fidelis leads. No independent multicenter long-term performance information exists for this lead, and single-center studies suggest that certain patients are at increased risk for Fidelis failure. Our aim was to assess the longevity of Fidelis leads and to evaluate clinical variables and adverse events associated with Fidelis failure. The results were compared with like data for Quattro Secure (Quattro) implantable cardioverter-defibrillator leads implanted at our centers. Methods and Results— This 3-center study included adults ≥18 years of age who received Fidelis or Quattro leads for the prevention of sudden cardiac death. From November 2001 to January 2009,1023 Fidelis and 1668 Quattro leads were implanted and followed up. The failure rate for Fidelis leads was 2.81%/y compared with 0.43%/y for Quattro leads ( P <0.0001). No deaths or injuries occurred as a result of lead failure, but 42% of fractures caused inappropriate shocks. The survival of Fidelis leads at 4 years was 87.0% (95% confidence interval, 83.6 to 90.1) compared with 98.7% (95% confidence interval, 97.9 to 99.4) for Quattro leads ( P <0.0001). Multivariate predictors of Fidelis failure were younger age (hazard ratio, 0.98; 95% confidence interval, 0.96 to 0.99), female gender (hazard ratio, 0.61; 95% confidence interval, 0.40 to 1.00), and cardiac disease ( P =0.041). Conclusions— Compared with Quattro leads, the survival of Fidelis leads continues to decline, and Fidelis failure is notably higher in younger patients, women, individuals with hypertrophic cardiomyopathy, and patients with arrhythmogenic right ventricular dysplasia or channelopathies. These findings have significant implications for the management of patients who have Fidelis leads, and they demonstrate the importance of weighing clinical variables in assessments of implantable cardioverter-defibrillator lead performance.
Gα13 and Rho Mediate Endosomal Trafficking of CXCR4 into Rab11+ Vesicles upon Stromal Cell-Derived Factor-1 Stimulation
Kremer, Kimberly N. , Tadi, Madhavi, Hedin, Karen E. , Kumar, Ashok , Domínguez, Daniel

Mayo Clinic

The Journal of Immunology | December 8, 2010 | Volume: 186 | Issue: 2 | Pages: 951-958

10.4049/jimmunol.1002019 | PMID 21148034 Get It

Abstract CXCR4, like other G protein-coupled receptors, signals via heterotrimeric guanine nucleotide-binding proteins (G proteins) to regulate gene transcription, migration, development, growth, and transformation. We describe a formerly uncharacterized function of a G protein: a role in receptor trafficking. We previously showed that CXCR4 and the TCR physically associate and form a heterodimer upon stromal cell-derived factor-1 or CXCL12 (SDF-1) stimulation in human T cells to prolong ERK activation and, thereby, lead to gene upregulation and cytokine secretion. The CXCR4–TCR heterodimers occur on the cell surface and in an intracellular compartment in response to SDF-1. Neither the intracellular compartment to which the CXCR4–TCR heterodimers localize nor the mechanism for localization has been elucidated. In this article, we characterize molecular mechanisms required for postendocytic trafficking of CXCR4. Upon SDF-1 stimulation, CXCR4 localizes to Rab11+ vesicles, a recycling compartment near the microtubule organizing center and Golgi apparatus. This trafficking requires the CXCR4 C-terminal tail domain but not the CXCR4 ubiquitination sites. The TCR also constitutively localizes to this Rab11+ compartment. Trafficking of CXCR4 into the Rab11+, TCR-containing endosomes requires actin polymerization. Furthermore, inhibiting Rho activation or depleting Gα13 prevented trafficking of CXCR4 into the Rab11+ endosomes without hindering the ability of CXCR4 to endocytose. These results indicated that, upon SDF-1 treatment, Gα13 and Rho mediate the actin polymerization necessary for trafficking CXCR4 into the Rab11+, recycling endosomal compartment, which also contains constitutively recycling TCR and, thus, CXCR4–TCR heterodimers. To our knowledge, this is the first report of Gα13 as a mediator of receptor trafficking.
Relationships Between Thyroid Function and Lipid Status or Insulin Resistance in a Pediatric Population
Nader, Nicole S., Bahn, Rebecca S. , Johnson, Michael D. , Weaver, Amy L. , Kumar, Seema , Nader, Nicole S., Singh, Ravinder J.

Mayo Clinic

Thyroid | November 29, 2010 | Volume: 20 | Issue: 12 | Pages: 1333-1339

10.1089/thy.2010.0180 | PMID 21114382 Get It

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
Kumar, Shaji , Dispenzieri, Angela , Katzmann, Jerry A., Colby, Colin , Lacy, Martha Q. , Hayman, Suzanne R. , Leung, Nelson , Zeldenrust, Steve R., Ramı́rez-Alvarado, Marina , Clark, Raynell, Kyle, Robert A. , Rajkumar, S. Vincent , Larson, Dirk R. , Buadi, Francis K. , Zeldenrust, Steven R., Gertz, Morie A. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Ramirez-Alvarado, Marina

Mayo Clinic

Blood | August 26, 2010 | Volume: 116 | Issue: 24 | Pages: 5126-5129

10.1182/blood-2010-06-290668 | PMID 20798235 Get It

Abstract Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC−uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
Kyle, Robert A. , Colby, Colin , Kumar, Shaji , Katzmann, Jerry A., Dispenzieri, Angela , Therneau, Terry M. , Cerhan, James R. , Melton, L. Joseph, Rajkumar, S. Vincent , Bianchi, Giada , Larson, Dirk R. , Rajkumar, S Vincent , Dispenzieri, Angela , Cerhan, James R

Mayo Clinic

Blood | May 21, 2010 | Volume: 116 | Issue: 12 | Pages: 2019-2025

10.1182/blood-2010-04-277566 | PMID 20495076 Get It

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is associated with a long-term risk of progression to multiple myeloma (MM) or related malignancy. To prevent serious myeloma-related complications, lifelong annual follow-up has been recommended, but its value is unknown. We reviewed all patients from southeastern Minnesota seen at Mayo Clinic between 1973 and 2004 with MGUS who subsequently progressed to MM. Of 116 patients, 69% had optimal follow-up of MGUS. Among these, abnormalities on serial follow-up laboratory testing led to the diagnosis of MM in 16%, whereas MM was diagnosed only after serious MM-related complications in 45%. In the remaining, workup of less serious symptoms (25%), incidental finding during workup of unrelated medical conditions (11%), and unknown (3%) were the mechanisms leading to MM diagnosis. High-risk MGUS patients (≥ 1.5 g/dL and/or non-IgG MGUS) were more likely to be optimally followed (81% vs 64%), and be diagnosed with MM secondary to serial follow-up testing (21% vs 7%). This retrospective study suggests that routine annual follow-up of MGUS may not be required in low-risk MGUS. Future studies are needed to replicate and expand our findings and to determine the optimal frequency of monitoring in higher-risk MGUS patients.
Proton pump inhibitor treatment for acute peptic ulcer bleeding
Sharma, Virender Kumar , Leontiadis, Grigorios I. , Howden, Colin W.

Mayo Clinic

Cochrane Database of Systematic Reviews | May 11, 2010 | Volume: 2010 | Issue: 5 | Pages: No page available

10.1002/14651858.cd002094.pub4 | PMID 20464720 Get It